Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 62,800 shares, a decrease of 14.3% from the September 30th total of 73,300 shares. Based on an average trading volume of 115,100 shares, the short-interest ratio is currently 0.5 days.
Coloplast A/S Stock Performance
Shares of Coloplast A/S stock opened at $12.75 on Thursday. The business’s fifty day simple moving average is $13.31 and its 200 day simple moving average is $12.85. The company has a current ratio of 0.85, a quick ratio of 0.56 and a debt-to-equity ratio of 1.00. Coloplast A/S has a 12 month low of $9.90 and a 12 month high of $14.34. The firm has a market capitalization of $27.54 billion, a P/E ratio of 38.64, a price-to-earnings-growth ratio of 3.30 and a beta of -0.02.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its earnings results on Tuesday, August 20th. The company reported $0.08 earnings per share (EPS) for the quarter. The firm had revenue of $993.49 million during the quarter. Coloplast A/S had a return on equity of 31.39% and a net margin of 18.89%. As a group, analysts anticipate that Coloplast A/S will post 0.34 EPS for the current year.
Coloplast A/S Company Profile
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.
Read More
- Five stocks we like better than Coloplast A/S
- With Risk Tolerance, One Size Does Not Fit All
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Breakout Stocks: What They Are and How to Identify Them
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Basic Materials Stocks Investing
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.